GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles
- PMID: 31711910
- DOI: 10.1016/j.jclinepi.2019.10.015
GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles
Abstract
Objectives: To provide GRADE guidance on how to prepare Summary of Findings tables and Evidence Profiles for time-to-event outcomes with a focus on the calculation of the corresponding absolute effect estimates.
Study design and setting: This guidance was justified by a research project identifying frequent errors and limitations in the presentation of time-to-event outcomes in the Summary of Findings tables. We developed this guidance through an iterative process that included membership consultation, feedback, presentation, and discussion at meetings of the GRADE Working Group.
Results: Review authors need to carefully consider the definition of the outcome of interest; although often the event is used as label for the outcome of interest (e.g., death or mortality), the event-free survival (e.g., overall survival) is reported throughout individual studies. Review authors should calculate the absolute effect correctly, either for the event or absence of the event. We also provide examples on how to calculate the absolute effects for events and the absence of events for various baseline or control group risks and time points.
Conclusions: This article aids in the development of Summary of Findings tables and Evidence Profiles, including time-to-event outcomes, and addresses the most common scenarios when calculating absolute effects in order to provide an accurate interpretation.
Keywords: Absolute effects; Evidence Profile; GRADE guidance; Hazard ratio; Summary of findings table; Time-to-event outcomes.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
[GRADE guidelines: 12. Developing Summary of Findings tables - dichotomous outcomes].Z Evid Fortbild Qual Gesundhwes. 2013;107(9-10):646-64. doi: 10.1016/j.zefq.2013.10.034. Epub 2013 Nov 9. Z Evid Fortbild Qual Gesundhwes. 2013. PMID: 24315336 German.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews.J Clin Epidemiol. 2019 Apr;108:1-9. doi: 10.1016/j.jclinepi.2018.12.006. Epub 2018 Dec 10. J Clin Epidemiol. 2019. PMID: 30543910 Review.
-
Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments.J Clin Epidemiol. 2016 Jun;74:28-39. doi: 10.1016/j.jclinepi.2015.12.006. Epub 2016 Jan 12. J Clin Epidemiol. 2016. PMID: 26796947
-
[GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles - continuous outcomes].Z Evid Fortbild Qual Gesundhwes. 2014;108(5-6):333-47. doi: 10.1016/j.zefq.2014.05.002. Epub 2014 Jul 2. Z Evid Fortbild Qual Gesundhwes. 2014. PMID: 25066353 German.
Cited by
-
Day care as a strategy for drowning prevention in children under 6 years of age in low- and middle-income countries.Cochrane Database Syst Rev. 2021 Apr 22;4(4):CD014955. doi: 10.1002/14651858.CD014955. Cochrane Database Syst Rev. 2021. PMID: 33884613 Free PMC article.
-
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.CMAJ. 2020 Jul 6;192(27):E734-E744. doi: 10.1503/cmaj.200647. Epub 2020 Jun 3. CMAJ. 2020. PMID: 32493740 Free PMC article.
-
Exploring the characteristics, methods and reporting of systematic reviews with meta-analyses of time-to-event outcomes: a meta-epidemiological study.BMC Med Res Methodol. 2024 Nov 25;24(1):291. doi: 10.1186/s12874-024-02401-4. BMC Med Res Methodol. 2024. PMID: 39587509 Free PMC article.
-
Janus kinase inhibitors for the treatment of COVID-19.Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD015209. doi: 10.1002/14651858.CD015209. Cochrane Database Syst Rev. 2022. PMID: 35695334 Free PMC article.
-
Hyperimmune immunoglobulin for people with COVID-19.Cochrane Database Syst Rev. 2023 Jan 26;1(1):CD015167. doi: 10.1002/14651858.CD015167.pub2. Cochrane Database Syst Rev. 2023. PMID: 36700518 Free PMC article.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources